Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Nonpseudophakic Cystoid Macular Edema Treatment & Management

  • Author: Daniel B Roth, MD; Chief Editor: Hampton Roy, Sr, MD  more...
 
Updated: Aug 21, 2014
 

Medical Care

Uveitis/inflammation

Steroids are considered an effective treatment to uveitis, administered in 3 different ways: topical, oral, and injectable.

Topical steroids and nonsteroidal anti-inflammatory agents have been used in the treatment of CME, especially when associated with uveitis. Most studies have evaluated the efficacy of these drugs in the presence of pseudophakic CME after cataract surgery.[2] However, the effect of these medications in stabilizing the blood-retinal barrier may aid in the treatment of other forms of CME.

Oral steroids also are a commonly used modality of stabilizing the blood-retinal barrier for the treatment of inflammation and CME in patients with intermediate or posterior uveitis. Oral steroids should be avoided unless necessary because of the associated complications of systemic use (eg, aseptic necrosis of the femoral head).

Injections of long-acting depot steroids (eg, triamcinolone) into the sub-Tenon space usually are more effective and commonly are used in the treatment of noninfectious uveitis. Peribulbar injections have a greater risk of intraocular injection than a subconjunctival approach; however, the drug delivery to the retina is superior when administered into the posterior sub-Tenon space. These implants allow sustained release of the steroid, maximizing drug efficiency and minimizing toxicity. Three potential candidates are undergoing clinical trials: dexamethasone implant (Posurdex), triamcinolone acetonide implant (I-vation TA), and fluocinolone acetonide implant (Retisert, which is FDA approved).

Intraocular triamcinolone acetonide has been found to effectively, but temporarily, reverse CME in eyes with many conditions, including pseudophakic CME, retinal vein occlusions, diabetic macular edema, uveitis, and juxtafoveal telangiectasis. Clinical trials are underway to study the long-term benefit and safety of this treatment approach.

Many other causes of CME are treated by addressing the underlying condition. CME associated with CMV retinitis is treated by managing the retinitis with antiviral agents (eg, ganciclovir, foscarnet, cidofovir).

CME associated with immune recovery in patients with inactive CMV retinitis and a stronger immune system are also treated with steroids, either oral or posterior sub-Tenon injection of long-acting depot steroids.

Orbital pseudotumor is treated effectively with oral steroids, and, in the case reported to be associated with CME, the macular edema resolved with treatment of the orbital pseudotumor.

Diabetic maculopathy

As stated, intraocular triamcinolone acetonide is an effective treatment for diabetic macular edema.

Research implicates VEGF as an important mediator of vascular permeability and CME. Therefore, clinical trials are being conducted to evaluate the benefit of VEGF inhibitors in treating CME associated with different conditions, such as diabetic macular edema, retinal vein occlusions, and age-related macular degeneration.[3] Anti-VEGF treatments also stunt neovascularization.

When CME is associated with diabetic macular edema, focal laser photocoagulation according to the guidelines of the Early Treatment of Diabetic Retinopathy Study (ETDRS) should be followed (see Diabetic Macular Edema). However, CME in the setting of diabetic macular edema often suggests chronicity of the condition and will not respond adequately to laser treatment. Some physicians advocate the use of posterior sub-Tenon or intraocular injection of triamcinolone with or without macular laser photocoagulation to treat diabetic macular edema associated with CME.

Age-related macular degeneration

CME associated with choroidal neovascularization in ARMD is a secondary response to the presence of subretinal neovascularization. It is present most commonly in eyes with significant subsensory fluid in the macula and a poor prognosis for central vision. Fortunately, current treatments of exudative ARMD reduce the incidence of disciform scarring and associated CME.

The FDA has approved 2 VEGF inhibitors to treat ARMD, pegaptanib sodium (Macugen) and ranibizumab (Lucentis)

Retinal vein occlusions

Intraocular triamcinolone acetonide and VEGF inhibitors have been found to reverse CME in eyes with retinal vein occlusions.

Currently, anti-VEGF agents are the primary treatment for retinal vein occlusion, specifically ranibizumab. Alongside, the Posurdex Study is evaluating the benefit of an injectable dexamethasone implant for the treatment of macular edema in retinal vein occlusions.

Intravitreal triamcinolone has been reported to be effective in reversing CME in branch retinal vein occlusion and nonischemic central retinal vein occlusion.[4, 5] The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study, a clinical trial sponsored by the National Institutes of Health (NIH), is evaluating the benefit of preservative-free intraocular triamcinolone acetonide in retinal vein occlusions.

Macular edema is a common cause of visual loss in eyes with branch retinal vein occlusion or central retinal vein occlusion. CME also can be associated with this form of macular edema. Macular laser photocoagulation has been shown to be effective in improving vision in patients with branch retinal vein occlusion for greater than 4 months’ duration and a visual acuity of 20/40 or worse. However, the Central Vein Occlusion Study (CVOS) did not show any visual benefit from laser photocoagulation in eyes with central retinal vein occlusion and macular edema, although it did reduce the macular edema.

Choroidal melanoma

When malignant intraocular tumors are associated with CME, the priority is to treat the tumor. Systemic malignancies, such as multiple myeloma, have been observed to be associated with CME. Systemic treatment of the myeloma is the priority and usually addresses the CME. However, sub-Tenon injection of steroid may enhance resolution of the CME in such cases. Depending on the nature of the disease, CME associated with intraocular tumors requires treatment of the tumor (eg, laser photocoagulation, cryotherapy, radiation, thermotherapy, enucleation).

Juxtafoveal macular telangiectasis

Treatment of CME associated with juxtafoveal telangiectasis has been undergoing preliminary trials with steroids, VEGF antibodies, and laser photocoagulation. Results show that intraocular triamcinolone acetonide temporarily lessens CME, but it recurs less than 6 months after treatment. Both bevacizumab and ranibizumab are being tested to reduce CME. Results show success in improving vision and CME for up to 12 months.[6]

CME secondary to juxtafoveal telangiectasis in Coats disease has been shown to respond to laser photocoagulation, with resolution of the edema and improvement in visual acuity, and remains the prevalent form of treatment.

Drug-induced and postoperative CME

Macular edema secondary to radiation retinopathy is often treated with laser photocoagulation.

CME after surgical interventions such as retinal reattachment surgery, corneal relaxing incisions, and keratoplasty usually resolve with time.

In drug-induced cases, such as CME associated with latanoprost, echothiophate iodide, or nicotinic acid, discontinuation of the drug usually causes reversal of CME.

Genetic disorders

O ther forms of CME have been reported to respond to treatment with acetazolamide. CME after scleral buckling procedures, CME in some forms of uveitis, and CME associated with RP may respond to acetazolamide therapy.

 
 
Contributor Information and Disclosures
Author

Daniel B Roth, MD Assistant Professor, Department of Ophthalmology, Retina Vitreous Center, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School

Daniel B Roth, MD is a member of the following medical societies: American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, American Society of Retina Specialists, Retina Society, American Medical Association

Disclosure: Nothing to disclose.

Coauthor(s)

Howard F Fine, MD, MHSc Partner, Associated Retina Consultants, Retina Vitreous Center, PA; Co-founder and Chairman of Scientific Advisory Board, Auris Surgical Robotics, Inc

Howard F Fine, MD, MHSc is a member of the following medical societies: American Academy of Ophthalmology, American Medical Association, Association for Research in Vision and Ophthalmology, American Society of Retina Specialists

Disclosure: Nothing to disclose.

Tahia Haque University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School

Disclosure: Nothing to disclose.

Specialty Editor Board

Simon K Law, MD, PharmD Clinical Professor of Health Sciences, Department of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, David Geffen School of Medicine

Simon K Law, MD, PharmD is a member of the following medical societies: American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, American Glaucoma Society

Disclosure: Nothing to disclose.

Steve Charles, MD Director of Charles Retina Institute; Clinical Professor, Department of Ophthalmology, University of Tennessee College of Medicine

Steve Charles, MD is a member of the following medical societies: American Academy of Ophthalmology, American Society of Retina Specialists, Macula Society, Retina Society, Club Jules Gonin

Disclosure: Received royalty and consulting fees for: Alcon Laboratories.

Chief Editor

Hampton Roy, Sr, MD Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Hampton Roy, Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, Pan-American Association of Ophthalmology

Disclosure: Nothing to disclose.

Additional Contributors

V Al Pakalnis, MD, PhD Professor of Ophthalmology, University of South Carolina School of Medicine; Chief of Ophthalmology, Dorn Veterans Affairs Medical Center

V Al Pakalnis, MD, PhD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, South Carolina Medical Association

Disclosure: Nothing to disclose.

References
  1. Moroi SE, Gottfredsdottir MS, Schteingart MT, Elner SG, Lee CM, Schertzer RM, et al. Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension. Ophthalmology. 1999 May. 106(5):1024-9. [Medline].

  2. Sivaprasad S, Bunce C, Crosby-Nwaobi R. Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery. Cochrane Database Syst Rev. 2012 Feb 15. 2:CD004239. [Medline].

  3. Ciulla TA, Rosenfeld PJ. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration. Curr Opin Ophthalmol. 2009 May. 20(3):166-74. [Medline].

  4. Liu L, Wu X, Geng J, Yuan Z, Chen L. IVTA as Adjunctive Treatment to PRP and MPC for PDR and Macular Edema: A Meta-Analysis. PLoS One. 2012. 7(9):e44683. [Medline]. [Full Text].

  5. Parke DW 3rd, Sisk RA, Murray TG. Intraoperative intravitreal triamcinolone decreases macular edema after vitrectomy with phacoemulsification. Clin Ophthalmol. 2012. 6:1347-53. [Medline]. [Full Text].

  6. Bressler SB, Qin H, Beck RW, Chalam KV, Kim JE, Melia M, et al. Factors Associated With Changes in Visual Acuity and Central Subfield Thickness at 1 Year After Treatment for Diabetic Macular Edema With Ranibizumab. Arch Ophthalmol. 2012 Sep 1. 130(9):1153-1161. [Medline].

  7. Gregori NZ, Gaitan J, Rosenfeld PJ, Puliafito CA, Feuer W, Flynn HW Jr, et al. Long-term safety and efficacy of intravitreal bevacizumab (Avastin) for the management of central retinal vein occlusion. Retina. 2008 Oct. 28(9):1325-37. [Medline].

  8. Arevalo JF, Garcia-Amaris RA. Intravitreal bevacizumab for diabetic retinopathy. Curr Diabetes Rev. 2009 Feb. 5(1):39-46. [Medline].

  9. Altintas O, Yuksel N, Karabas VL, Demirci G. Cystoid macular edema associated with latanoprost after uncomplicated cataract surgery. Eur J Ophthalmol. 2005 Jan-Feb. 15(1):158-61. [Medline].

  10. Antcliff RJ, Spalton DJ, Stanford MR, Graham EM, ffytche TJ, Marshall J. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology. 2001 Apr. 108(4):765-72. [Medline].

  11. Boscia F, Furino C, Dammacco R. Intravitreal triamcinolone acetonide in refractory pseudophakic cystoid macular edema: functional and anatomic results. Eur J Ophthalmol. 2005 Jan-Feb. 15(1):89-95. [Medline].

  12. Callanan D, Fellman RL, Savage JA. Latanoprost-associated cystoid macular edema. Am J Ophthalmol. 1998 Jul. 126(1):134-5. [Medline].

  13. Conway MD, Canakis C, Livir-Rallatos C. Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular edema. J Cataract Refract Surg. 2003 Jan. 29(1):27-33. [Medline].

  14. Falcone PM. Vitreomacular traction syndrome confused with pseudophakic cystoid macular edema. Ophthalmic Surg Lasers. 1996 May. 27(5):392-4. [Medline].

  15. Feldman RB, Mayo SS, Robertson DM, Jones JD, Rostvold JA. Epiretinal membranes and cystoid macular edema in gyrate atrophy of the choroid and retina. Retina. 1989. 9(2):139-42. [Medline].

  16. Fung WE. Retina. Other causes of cystoid macular edema and retinal trauma after surgery. 1994. 2(2): 1811-7.

  17. Gregori NZ, Rosenfeld PJ, Puliafito CA, Flynn HW Jr, Lee JE, Mavrofrides EC, et al. One-year safety and efficacy of intravitreal triamcinolone acetonide for the management of macular edema secondary to central retinal vein occlusion. Retina. 2006 Oct. 26(8):889-95. [Medline].

  18. Halperin LS, Goldman HB. Cystoid macular edema associated with topical echothiophate iodide. Ann Ophthalmol. 1993 Dec. 25(12):457-8. [Medline].

  19. Heckenlively JR, Jordan BL, Aptsiauri N. Association of antiretinal antibodies and cystoid macular edema in patients with retinitis pigmentosa. Am J Ophthalmol. 1999 May. 127(5):565-73. [Medline].

  20. Heier JS, Steinert RF, Frederick AR Jr. Cystoid macular edema associated with latanoprost use. Arch Ophthalmol. 1998 May. 116(5):680-2. [Medline].

  21. Hirakawa H, Iijima H, Gohdo T, Tsukahara S. Optical coherence tomography of cystoid macular edema associated with retinitis pigmentosa. Am J Ophthalmol. 1999 Aug. 128(2):185-91. [Medline].

  22. Igarashi H, Igarashi S, Ishiko S, Fukui K, Yoshida A. Cystoid macular edema as an initial symptom of inflammatory orbital pseudotumor. Ophthalmologica. 1997. 211(4):236-41. [Medline].

  23. Ikeda T, Sato K, Katano T, Hayashi Y. Attached posterior hyaloid membrane and the pathogenesis of honeycombed cystoid macular edema in patients with diabetes. Am J Ophthalmol. 1999 Apr. 127(4):478-9. [Medline].

  24. Ip MS, Gottlieb JL, Kahana A, Scott IU, Altaweel MM, Blodi BA, et al. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. Arch Ophthalmol. 2004 Aug. 122(8):1131-6. [Medline].

  25. Jonas JB, Akkoyun I, Kamppeter B, Kreissig I, Degenring RF. Branch retinal vein occlusion treated by intravitreal triamcinolone acetonide. Eye. 2005 Jan. 19(1):65-71. [Medline].

  26. Kersten AJ, Althaus C, Best J, Sundmacher R. Cystoid macular edema following immune recovery and treatment with cidofovir for cytomegalovirus retinitis. Graefes Arch Clin Exp Ophthalmol. 1999 Nov. 237(11):893-6. [Medline].

  27. Kim BY, Smith SD, Kaiser PK. Optical coherence tomographic patterns of diabetic macular edema. Am J Ophthalmol. 2006 Sep. 142(3):405-12. [Medline].

  28. Lee ST, Friedman SM, Rubin ML. Cystoid macular edema secondary to juxtafoveolar telangiectasis in Coats' disease. Ophthalmic Surg. 1991 Apr. 22(4):218-21. [Medline].

  29. Loeffler KU, Li ZL, Fishman GA, Tso MO. Dominantly inherited cystoid macular edema. A histopathologic study. Ophthalmology. 1992 Sep. 99(9):1385-92. [Medline].

  30. Maguire AM, Nichols CW, Crooks GW. Visual loss in cytomegalovirus retinitis caused by cystoid macular edema in patients without the acquired immune deficiency syndrome. Ophthalmology. 1996 Apr. 103(4):601-5. [Medline].

  31. McDonnell PJ, Ryan SJ, Walonker AF, Miller-Scholte A. Prediction of visual acuity recovery in cystoid macular edema. Ophthalmic Surg. 1992 May. 23(5):354-8. [Medline].

  32. Meyer CH. Current treatment approaches in diabetic macular edema. Ophthalmologica. 2007. 221(2):118-31. [Medline].

  33. Michael JC, De Venecia G. Retinal trypsin digest study of cystoid macular edema associated with peripheral choroidal melanoma. Am J Ophthalmol. 1995 Feb. 119(2):152-6. [Medline].

  34. Mishima H, Masuda K, Miyake K. The putative role of prostaglandins in cystoid macular edema. Prog Clin Biol Res. 1989. 312:251-64. [Medline].

  35. Park CH, Jaffe GJ, Fekrat S. Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. Am J Ophthalmol. 2003 Sep. 136(3):419-25. [Medline].

  36. Park DW, Folk JC, Whitcup SM, Polk TD, Kansupada K, Fountain C, et al. Phakic patients with cystoid macular edema, retinal periphlebitis, and vitreous inflammation. Arch Ophthalmol. 1998 Aug. 116(8):1025-9. [Medline].

  37. Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina. 2007 Apr-May. 27(4):419-25. [Medline].

  38. Remky A, Beausencourt E, Hartnett ME, Trempe CL, Arend O, Elsner AE. Infrared imaging of cystoid macular edema. Graefes Arch Clin Exp Ophthalmol. 1999 Nov. 237(11):897-901. [Medline].

  39. Rocha G, Deschênes J. Pathophysiology and treatment of cystoid macular edema. Can J Ophthalmol. 1996 Oct. 31(6):282-8. [Medline].

  40. Rumelt S, Kraus E, Rehany U. Retinal neovascularization and cystoid macular edema in punctata albescens retinopathy. Am J Ophthalmol. 1992 Oct 15. 114(4):507-8. [Medline].

  41. Russo V, Barone A, Conte E, Prascina F, Stella A, Noci ND. Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion. Retina. 2009 Apr. 29(4):511-5. [Medline].

  42. Schubert HD. Cystoid macular edema: the apparent role of mechanical factors. Prog Clin Biol Res. 1989. 312:277-91. [Medline].

  43. Silverstein BE, Smith JH, Sykes SO, Jones MR, Schwartz D, Cunningham ET Jr. Cystoid macular edema associated with cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol. 1998 Mar. 125(3):411-5. [Medline].

  44. Thach AB, Dugel PU, Flindall RJ, Sipperley JO, Sneed SR. A comparison of retrobulbar versus sub-Tenon's corticosteroid therapy for cystoid macular edema refractory to topical medications. Ophthalmology. 1997 Dec. 104(12):2003-8. [Medline].

  45. van Kooij B, Rothova A, de Vries P. The pros and cons of intravitreal triamcinolone injections for uveitis and inflammatory cystoid macular edema. Ocul Immunol Inflamm. 2006 Apr. 14(2):73-85. [Medline].

  46. Weene LE. Cystoid macular edema after scleral buckling responsive to acetazolamide. Ann Ophthalmol. 1992 Nov. 24(11):423-4. [Medline].

  47. Welzl-Hinterkorner E, Tholen H, Sturmer J, Opravil M, Bernauer W. [Bilateral cystoid macular edema after successful treatment of AIDS-associated cytomegalovirus retinitis]. Ophthalmologe. 1999 Feb. 96(2):87-91. [Medline].

  48. Wen JC, McCannel TA. Treatment of radiation retinopathy following plaque brachytherapy for choroidal melanoma. Curr Opin Ophthalmol. 2009 May. 20(3):200-4. [Medline].

  49. Whitcup SM, Csaky KG, Podgor MJ, Chew EY, Perry CH, Nussenblatt RB. A randomized, masked, cross-over trial of acetazolamide for cystoid macular edema in patients with uveitis. Ophthalmology. 1996 Jul. 103(7):1054-62; discussion 1062-3. [Medline].

  50. Yepremyan M, Wertz FD, Tivnan T, Eversman L, Marx JL. Early treatment of cystoid macular edema secondary to branch retinal vein occlusion with intravitreal triamcinolone acetonide. Ophthalmic Surg Lasers Imaging. 2005 Jan-Feb. 36(1):30-6. [Medline].

 
Previous
Next
 
Fundus photograph of left eye with branch retinal vein occlusion and cystoid macular edema. Visual acuity was 20/50, and the patient was treated with a modified grid laser photocoagulation and posterior sub-Tenon injection of triamcinolone.
Fundus photograph of nonproliferative diabetic retinopathy with clinically significant macular edema and cystoid macular edema.
Fluorescein angiogram of same eye as in the image above, revealing both cystoid macular edema and leakage from microaneurysms associated with diabetic retinopathy.
Ocular coherence tomographic image of cystoid macular edema in a patient with uveitis.
Cystoid macular edema in patient with diabetic retinopathy.
Eye in previous image with diabetic CME after injection with 4 mg of intravitreal triamcinolone.
Ocular coherence tomographic image of cystoid macular edema in an eye with nonproliferative diabetic retinopathy.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.